Aclaris Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $1,629 | $1,996 | $1,295 | $3,299 |
Gross Profit | 1,398 | 1,601 | 2,098 | 2,761 |
EBITDA | -21,296 | -19,722 | -19,693 | -14,404 |
EBIT | -21,505 | -19,824 | -19,795 | -14,614 |
Net Income | -21,505 | -19,824 | -19,795 | -14,614 |
Net Change In Cash | 1,629 | 1,996 | 1,295 | 3,299 |
Free Cash Flow | -19,918 | -18,149 | -13,155 | -10,955 |
Cash | 19,167 | 28,660 | 19,960 | 25,256 |
Basic Shares | 142,736 | 128,810 | 122,664 | 122,619 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $7,826 | $18,720 | $31,249 | $29,752 |
Gross Profit | 5,735 | 15,928 | 13,168 | 17,792 |
EBITDA | -64,469 | -51,720 | -115,451 | -84,357 |
EBIT | -64,923 | -52,527 | -116,314 | -85,154 |
Net Income | -64,923 | -132,065 | -88,481 | -86,908 |
Net Change In Cash | 7,826 | 18,720 | 31,249 | 29,752 |
Cost of Revenue | 17,928 | |||
Free Cash Flow | -47,113 | -20,196 | -79,634 | -68,172 |
Cash | 19,960 | 24,570 | 39,878 | 45,277 |
Basic Shares | 122,664 | 77,296 | 69,808 | 65,213 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.15 |
2026-03-31 | -$0.15 |
2025-12-31 | -$0.16 |
2025-09-30 | -$0.12 |